Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in β thalassaemia

被引:66
作者
Saxon, BR
Rees, D
Olivieri, NF
机构
[1] Univ Toronto, Toronto, ON, Canada
[2] Univ Oxford, Inst Mol Med, Oxford, England
关键词
hydroxyurea; beta thalassaemia; extramedullary haemopoietic regression;
D O I
10.1046/j.1365-2141.1998.00719.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hydroxyurea increases fetal haemoglobin in many patients with sickle cell anaemia, but its effectiveness in thalassaemia appears to be less consistent. We describe the response to hydroxyurea in an adult male with homozygous beta thalassaemia, symptomatic paraspinal extramedullary haemopoiesis, bone pain, and progressive tissue iron loading. Prior to therapy with hydroxyurea the circulating haemoglobin (Hb) concentration was 7.0 g/dl and absolute fetal haemoglobin concentration was 5.0 g/dl. Administration of sodium phenylbutyrate had induced no increase in either parameter. Subsequent therapy with hydroxyurea was associated with increases in total haemoglobin to 9.0 g/dl, and in fetal haemoglobin to 7.6 g/dl. Ineffective erythropoiesis was reduced and extramedullary haemopoiesis regressed during therapy.
引用
收藏
页码:416 / 419
页数:4
相关论文
共 20 条
[1]  
ANSELM CW, 1996, PEDIAT HEMATOLOGY ON, V13, P89
[2]   Successful use of hydroxyurea in beta-thalassemia major [J].
Arruda, VR ;
Lima, CSP ;
Saad, STO ;
Costa, FF .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) :964-964
[3]  
BACHIR D, 1995, C INSERM, V234, P195
[4]   Hydroxyurea and sickle cell anemia - Clinical utility of a myelosuppressive ''switching'' agent [J].
Charache, S ;
Barton, FB ;
Moore, RD ;
Terrin, ML ;
Steinberg, MH ;
Dover, GJ ;
Ballas, SK ;
McMahon, RP ;
Castro, O ;
Orringer, EP ;
Jones, S ;
Strayhorn, D ;
Rosse, W ;
Phillips, G ;
Peace, D ;
JohnsonTelfair, A ;
Milner, P ;
Kutlar, A ;
Tracy, A ;
Allen, GE ;
Moshang, J ;
Steinberg, M ;
Anderson, A ;
Sabahi, V ;
Pegelow, C ;
Temple, D ;
Case, E ;
Harrell, R ;
Embury, S ;
Schmidt, B ;
Koshy, M ;
TalischyZahed, N ;
Dorn, L ;
Pendarvis, G ;
McGee, M ;
Telfer, M ;
Davis, A ;
Finke, H ;
Perlin, E ;
Siteman, J ;
Gascon, P ;
diPaolo, P ;
Gargiulo, S ;
Eckman, J ;
Bailey, JH ;
Platt, A ;
Waller, L ;
Ramirez, G ;
Knors, V ;
Hernandez, S .
MEDICINE, 1996, 75 (06) :300-326
[5]  
COHEN AR, 1995, COLLOQ INSE, V234, P193
[6]   ORAL SODIUM PHENYLBUTYRATE THERAPY IN HOMOZYGOUS BETA-THALASSEMIA - A CLINICAL-TRIAL [J].
COLLINS, AF ;
PEARSON, HA ;
GIARDINA, P ;
MCDONAGH, KT ;
BRUSILOW, SW ;
DOVER, GJ .
BLOOD, 1995, 85 (01) :43-49
[7]   Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia hemoglobin E disease [J].
Fucharoen, S ;
Siritanaratkul, N ;
Winichagoon, P ;
Chowthaworn, J ;
Siriboon, W ;
Muangsup, W ;
Chaicharoen, S ;
Poolsup, N ;
Chindavijak, B ;
Pootrakul, P ;
Piankijagum, A ;
Schechter, AN ;
Rodgers, GP .
BLOOD, 1996, 87 (03) :887-892
[8]  
GONZALEZREDONDO JM, 1988, BLOOD, V72, P1007
[9]   PHARMACOLOGICAL TREATMENT OF THALASSEMIA-INTERMEDIA WITH HYDROXYUREA [J].
HAJJAR, FM ;
PEARSON, HA .
JOURNAL OF PEDIATRICS, 1994, 125 (03) :490-492
[10]  
HUANG SZ, 1994, SCI CHINA SER B, V37, P1350